Recent News 13 : SNIPR001 Enters Clinical Trials as CRISPR-Engineered Phage Therapy Targets Drug-Resistant E. coli in Cancer Patients

Danish biotechnology company SNIPR Biome has reached an important milestone in precision antimicrobial medicine with the first dosing of a cancer patient in its Phase 1b clinical trial evaluating SNIPR001, a CRISPR-engineered bacteriophage therapy designed to selectively eliminate antibiotic-resistant Escherichia coli. The trial represents one of the most advanced clinical applications yet of programmable phage therapeutics and highlights the growing convergence between synthetic biology, microbiome science, and infectious disease medicine.

The study focuses on a particularly vulnerable patient population: individuals with hematological malignancies undergoing hematopoietic stem cell transplantation. Although these procedures are often lifesaving, they also produce profound immunosuppression, leaving patients highly susceptible to severe bacterial infections during periods of neutropenia. In this setting, fluoroquinolone-resistant E. coli has become a major clinical concern, accounting for a substantial proportion of bloodstream infections while increasingly evading standard prophylactic antibiotics.

The Phase 1b trial is a randomized, double-blind, placebo-controlled study enrolling twenty-four patients across multiple clinical centers in the United States. Researchers are evaluating the safety, tolerability, and microbiological activity of SNIPR001 in patients undergoing either allogeneic or autologous stem cell transplantation.

What makes SNIPR001 particularly significant is its mechanism of action. Unlike conventional antibiotics, which broadly disrupt microbial ecosystems, the therapy is composed of four genetically engineered bacteriophages specifically designed to target fluoroquinolone-resistant E. coli strains while preserving beneficial components of the intestinal microbiota. This precision-based strategy addresses one of the central limitations of modern antibiotic therapy: collateral microbiome damage.

Figure 1. An overview of the SNIPR001 creation process. Wild-type phages screened against diverse E. coli strains, then engineered with tail fibers and CRISPR-CAS systems to create four complementary CAPs targeting fluoroquinolone-resistant E. coli in neutropenic cancer patients. Reproduced under the Creative Commons License from Gencay et al. (2023) https://doi.org/10.1038/s41587-023-01759-y

The therapy was developed through large-scale screening of 162 wild-type phages against hundreds of genetically diverse clinical E. coli isolates. From this collection, researchers selected highly active candidates and further enhanced them using two layers of engineering. The first involved modification of phage tail fibers to improve bacterial recognition and host specificity. The second integrated CRISPR-Cas systems directly into the phage genomes, allowing the viruses to selectively degrade bacterial DNA after infection.

This combination effectively transforms bacteriophages into programmable antibacterial vectors capable of targeting resistance-associated bacterial populations with exceptional specificity. By attacking fluoroquinolone-resistant strains directly within the gut microbiome, SNIPR001 aims to reduce the risk of systemic bloodstream infections without inducing the widespread ecological disruption associated with broad-spectrum antibiotics.

The microbiome-preserving aspect of the therapy may prove especially important in oncology patients. Conventional prophylactic antibiotics frequently destabilize intestinal microbial communities, creating conditions favorable to opportunistic pathogens such as Clostridioides difficile or multidrug-resistant organisms. Increasing evidence also suggests that microbiome composition influences immune recovery, inflammation, and even therapeutic responses in cancer patients. Maintaining microbial balance while selectively removing pathogenic bacteria therefore represents a major conceptual shift in infectious disease management.

The current study builds upon encouraging Phase 1a results previously obtained in healthy volunteers. According to reported data, SNIPR001 demonstrated favorable safety and pharmacodynamic profiles, effective engagement of target E. coli populations, and minimal disruption of overall microbiota composition. No serious adverse events were observed during the earlier trial phase.

Scientifically, the program represents one of the clearest examples to date of CRISPR-assisted phage therapy transitioning from experimental concept to clinical reality. While bacteriophages naturally possess strong antibacterial activity, combining them with programmable CRISPR systems introduces an additional layer of molecular precision that may reduce the likelihood of bacterial escape and improve killing efficiency against resistant strains.

The broader implications extend far beyond E. coli infections in stem cell transplant patients. The underlying platform could theoretically be adapted against a wide range of bacterial pathogens, including Klebsiella pneumoniae, Pseudomonas aeruginosa, and Clostridioides difficile. More broadly, programmable phage systems may eventually enable antimicrobial therapies tailored not only to specific bacterial species, but also to individual resistance genes or patient microbiome profiles.

This approach reflects a growing realization that future antimicrobial therapies may need to operate with ecological precision rather than broad-spectrum destruction. As antimicrobial resistance continues to accelerate globally, therapies capable of selectively editing pathogenic bacterial populations while preserving beneficial microbiota could fundamentally reshape infectious disease treatment.

Although larger clinical studies will still be necessary to confirm efficacy and long-term safety, the launch of the SNIPR001 Phase 1b trial marks an important moment for the field. It demonstrates that engineered phage therapeutics are no longer confined to theoretical research or isolated compassionate-use cases, but are increasingly entering structured clinical development pathways.

In many ways, SNIPR001 represents a new generation of antimicrobial medicine, one where viruses are no longer viewed solely as biological threats, but as programmable therapeutic instruments capable of precisely reshaping microbial ecosystems.

Source : CRISPR Medicine News Report

Scientific source : https://doi.org/10.1038/s41587-023-01759-y